flanders.bio provides you with insights in the vibrant life sciences sector

 

News from flanders.bio and its members

Ablynx - Results from the Phase III Hercules Study of Caplacizumab for the treatment of acquired TTP selected for presentation in the late-breaking abstracts session at the 2017 ASH annual meeting

Ablynx NV [Euronext Brussels and Nasdaq: ABLX] today announced that results from its Phase III HERCULES study of caplacizumab have been selected as one of only six abstracts for oral presentation in the late-breaking abstracts session at the 59th Annual Meeting of the American Society of Hematology (ASH) taking place in Atlanta, GA, on 12 December 2017.

Research | 22 November 17
Read more
22
Nov
2017

Mithra Announces 36-month Shelf Life Extension for Tibelia®

Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today confirms the extended shelf-life of 36 months of its complex therapeutic product Tibelia®, as compared to 24 months for other currently available tibolone-based products.

22
Nov
2017

Galapagos initiates Phase 1 study with novel CF corrector GLPG3221

Galapagos NV (Euronext & NASDAQ: GLPG) announces initiation of a Phase 1 study with a novel C2 corrector GLPG3221 for cystic fibrosis (CF). Galapagos receives a $10 million milestone payment from its collaboration partner AbbVie for this achievement.

22
Nov
2017

Promethera Biosciences Provides Update on Executive Management Team

Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, today announced the promotion of Mark Johnston to Chief Commercial Officer of Promethera Biosciences group (Belgium) and Managing Director of Promethera Biosciences LLC (USA); and Jef Pinxteren, Ph.D., to Vice President Operations of Promethera Biosciences group, effective immediately. Both have more than 20 years of experience in the field of cell therapy.

21
Nov
2017

TiGenix to present positive 52-week Phase III Cx601 data at EHA-SWG Scientific Meeting

TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical conditions, today announces that the positive 52-week results from its ADMIRE-CD Phase III clinical trial of Cx601 for the treatment of complex perianal fistulas in patients with Crohn's disease will be presented at the EHA-SWG Scientific Meeting on Shaping the Future of Mesenchymal Stromal Cells Therapy taking place from November 23-25, 2017 in Amsterdam, Netherlands. TiGenix is a contributor of the meeting.

22
Nov
2017

Mithra Announces 36-month Shelf Life Extension for Tibelia®

Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today confirms the extended shelf-life of 36 months of its complex therapeutic product Tibelia®, as compared to 24 months for other currently available tibolone-based products.

22
Nov
2017

Galapagos initiates Phase 1 study with novel CF corrector GLPG3221

Galapagos NV (Euronext & NASDAQ: GLPG) announces initiation of a Phase 1 study with a novel C2 corrector GLPG3221 for cystic fibrosis (CF). Galapagos receives a $10 million milestone payment from its collaboration partner AbbVie for this achievement.

22
Nov
2017

Promethera Biosciences Provides Update on Executive Management Team

Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, today announced the promotion of Mark Johnston to Chief Commercial Officer of Promethera Biosciences group (Belgium) and Managing Director of Promethera Biosciences LLC (USA); and Jef Pinxteren, Ph.D., to Vice President Operations of Promethera Biosciences group, effective immediately. Both have more than 20 years of experience in the field of cell therapy.

21
Nov
2017

TiGenix to present positive 52-week Phase III Cx601 data at EHA-SWG Scientific Meeting

TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical conditions, today announces that the positive 52-week results from its ADMIRE-CD Phase III clinical trial of Cx601 for the treatment of complex perianal fistulas in patients with Crohn's disease will be presented at the EHA-SWG Scientific Meeting on Shaping the Future of Mesenchymal Stromal Cells Therapy taking place from November 23-25, 2017 in Amsterdam, Netherlands. TiGenix is a contributor of the meeting.

Facts & Figures

CONSULT OUR LIFE SCIENCE DATABASE

 

Innovation is at the core of the life sciences sector and Belgium has a track record of developing ingenious ways to improve the quality of life of millions of people worldwide.

 

Not only extensive life sciences facilities support this high-level technology industry but also financial benefits for R&D companies, international collaborations that guarantee regular cash flow, world known educational systems, a promising product pipeline, and Belgium’s unique central location in Europe.

 

Belgium concentrates on a small territory (30,528 km2) more than 300 life sciences companies with biotech activities. In total, the life sciences sector employs more than 30,000 people (low bound estimation that does not take into account indirect employment generated by the sector). The majority of the companies is related to healthcare, but Belgium also has a strong representation of agricultural and industrial biotech companies.

 

The growing life sciences sector gathers 8 main Belgian universities, 19 research parks and 23 incubators, research institutes, academic hospitals, and clinical research organizations. Biotech companies have access to more than 500,000 square feet of highly flexible infrastructure.

 

Additional assets of Belgium includes: a supportive regulatory and political environment, a highly qualified and productive workforce, a competitive tax environment especially for research companies, a prominent location and an excellent logistical and business infrastructure.

Z Life Sciences

A look behind the scenes of the vibrant life sciences sector in Flanders, Belgium in 11 episodes.

1

VIB

VIB is a life sciences research institute based in Flanders. With more than 1470 scientists from over 60 countries, they perform basic research into the molecular foundations of life and they translate this research into pharmaceutical, agricultural and industrial applications.

2

imec

imec performs world-leading research in nano-electronics and creates groundbreaking innovation in application domains such as healthcare, smart cities and mobility, logistics and manufacturing, and energy. The combination of their widely acclaimed leadership in microchip technology and profound software and ICT expertise is what makes imec unique.

3

Bio Base Europe Pilot Plant

Bio Base Europe Pilot Plant is an independent, state-of-the-art facility that operates from a laboratory level to a multi-ton scale. Bio Base Europe Pilot Plant provides process development, scale-up and custom manufacturing of biobased products and processes. 

 

E-letter archive

Interested in a regular update of the Life Sciences and biotech sector in Flanders?